Company profile: Encycle Therapeutics
1.1 - Company Overview
Company description
- Provider of a platform technology for rapid synthesis of drug-like macrocycles and membrane-permeable nacellins, which have potential to target intracellular protein-protein interactions largely intractable to small molecule and biologic modulation.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Encycle Therapeutics
Novellus Therapeutics
HQ: United States
Website
- Description: Provider of engineered cellular medicines using non-immunogenic mRNA molecules to safely and efficiently reprogram and gene-edit cells, engineering precision medicines for patient segments via a technology toolbox spanning in vivo and ex vivo applications, including allogeneic and autologous approaches.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novellus Therapeutics company profile →
Equillium
HQ: United States
Website
- Description: Provider of therapeutics for autoimmune and inflammatory disorders, including itolizumab, a clinical-stage monoclonal antibody targeting the CD6-ALCAM pathway; EQ101, a tri-specific cytokine inhibitor of IL-2/IL-9/IL-15 in Phase 2 for alopecia areata; EQ302, an oral bi-specific inhibitor of IL-15/IL-21 in pre-clinical; and a multi-cytokine platform generating composite peptides to selectively block key cytokines at shared receptors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Equillium company profile →
Delinia
HQ: United States
Website
- Description: Provider of novel therapeutics for autoimmune and inflammatory diseases, with a lead program focused on a molecule that selectively potentiates and expands regulatory T cells (Tregs), the immune cells critical to maintaining self-tolerance and immune system homeostasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delinia company profile →
Salzman Group
HQ: United States
Website
- Description: Provider of global drug development and biotechnology services focused on transformative pharmaceutical innovation, creating and developing its own drugs and those of others, serving both as an internal research engine and as a boutique contract service organization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Salzman Group company profile →
OMass Therapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery leveraging novel mass spectrometry, offering the OdyssION platform that uses native mass spectrometry and custom chemistry to study target interactions in native ecosystems, and a small molecule pipeline targeting solute carriers, inflammasome complexes, and GPCRs for orphan and immunological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OMass Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Encycle Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Encycle Therapeutics
2.2 - Growth funds investing in similar companies to Encycle Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Encycle Therapeutics
4.2 - Public trading comparable groups for Encycle Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →